Pharmaceutical Manufacturing Execution System Market Worth $4.62 Billion by 2030 - Exclusive Report by MarketsandMarkets
DELRAY BEACH, Fla, Dec. 15, 2025 /PRNewswire/ -- According to MarketsandMarkets, the Pharmaceutical Manufacturing Execution System market is expected to grow to USD 4.62 billion by 2030 from USD 2.37 billion in 2025, with a CAGR of 14.3% from 2025 to 2030.
佛羅里達州德雷海灘，2025年12月15日/PRNewswire/--根據MarketsandMarkets的數據，製藥製造執行系統市場預計將從2025年的23.7億美元增長到2030年的46.2億美元，從2025年到2030年的複合年增長率爲14.3%。
Browse 150 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on " Pharmaceutical Manufacturing Execution System Market - Global Forecast to 2030"
瀏覽分佈在250頁中的150個市場數據表和50幅圖表以及關於「製藥製造執行系統市場 - 2030年全球預測」的深入目錄。
Pharmaceutical Manufacturing Execution System Market Size & Forecast:
製藥製造執行系統市場規模和預測：
- Market Size Available for Years: 2020–2030
- 2025 Market Size: USD 2.37 billion
- 2030 Projected Market Size: USD 4.62 billion
- CAGR (2025–2030): 14.3%
- 可獲取市場規模的年份：2020–2030
- 2025年市場規模：23.7億美元
- 2030年預計市場規模：46.2億美元
- 複合年增長率（2025-2030）：14.3%
Pharmaceutical Manufacturing Execution System Market Trends & Insights:
製藥製造執行系統市場趨勢與洞察：
- Stringent global regulations, the need for electronic batch records, and increasing focus on data integrity are pushing pharma manufacturers to adopt MES. Rapid growth in biologics, vaccines, and high-complexity drugs further drives digitalization, real-time monitoring, and automated quality control, strengthening MES adoption across global pharmaceutical facilities.
- By Offering, the services segment is expected to register the highest CAGR of 15.3% during the forecast period.
- By Deployment, the cloud-based segment is expected to dominate the market in terms of market share.
- By region, the Asia Pacific is expected to dominate the market, with a market share reaching ~40% by 2030.
- 嚴格的全球法規、對電子批次記錄的需求以及對數據完整性的日益關注，正在推動製藥製造商採用MES。生物製品、疫苗和高複雜性藥物的快速增長進一步推動了數字化、實時監測和自動質量控制，加強了MES在全球製藥設施中的應用。
- 按產品分類，服務部分預計在預測期內將以最高的15.3%的複合年增長率增長。
- 按部署分類，基於雲的部分預計將在市場份額方面主導市場。
- 按地區劃分，預計到2030年亞太地區將主導市場，市場份額將達到約40%。
Download PDF Brochure:
Download PDF Brochure:
The pharmaceutical manufacturing execution system (MES) market is experiencing strong growth driven primarily by increasing regulatory pressures, the need for end-to-end batch visibility, and the rapid shift toward digitalized, paperless manufacturing. Regulatory frameworks such as FDA 21 CFR Part 11, EU Annex 11, GAMP 5, and global GMP standards are compelling pharmaceutical companies to adopt MES to ensure data integrity, electronic batch records (eBR), and real-time compliance monitoring. The rising complexity of drug formulations, personalized medicine, and multi-product facilities further accelerates the adoption of MES to enhance traceability, reduce deviations, and support faster batch release. Additionally, the increasing adoption of IIoT-enabled shop-floor automation, LIMS-MES-ERP integration, and digital quality systems is pushing manufacturers toward advanced MES solutions.
製藥製造執行系統（MES）市場正在經歷強勁增長，主要驅動力包括不斷增加的監管壓力、對端到端批次可見性的需求以及快速向數字化、無紙化製造轉變的趨勢。諸如FDA 21 CFR Part 11、歐盟附錄11、GAMP 5和全球GMP標準等監管框架正促使製藥公司採用MES以確保數據完整性、電子批記錄（eBR）和實時合規性監控。藥物配方複雜性的增加、個性化醫療以及多產品設施的興起進一步加速了對MES的採用，以增強可追溯性、減少偏差並支持更快的批次放行。此外，對啓用IIoT的車間自動化、LIMS-MES-ERP集成和數字質量系統的日益採用也推動製造商轉向先進的MES解決方案。
The market is also driven by expanding biopharmaceutical production, the rise of continuous manufacturing, and the need for improved productivity and operational efficiency. Pharmaceutical firms are increasingly investing in MES to improve process reliability, reduce operational errors, optimize production costs, and support real-time performance analytics. Growing R&D activities, global supply chain pressures, and the expansion of biologics and vaccine manufacturing are reinforcing the demand for agile, scalable MES platforms. Moreover, cloud-based and hybrid MES models are gaining traction, enabling multi-site harmonization, faster implementation cycles, and lower IT burden, thereby accelerating overall MES deployment in the pharmaceutical industry.
市場還受到生物製藥生產擴張、連續製造的興起以及提高生產力和運營效率需求的推動。製藥企業越來越多地投資MES以提高工藝可靠性、減少操作錯誤、優化生產成本並支持實時性能分析。不斷增長的研發活動、全球供應鏈壓力以及生物製品和疫苗製造的擴展進一步加強了對靈活、可擴展MES平台的需求。此外，基於雲和混合MES模型正在獲得關注，從而實現多站點協調、更快的實施週期和更低的IT負擔，從而加速整個製藥行業的MES部署。
The cloud-based deployment in the pharmaceutical MES market is expected to hold the highest market share in 2030.
預計到2030年，基於雲的部署在製藥MES市場中將佔據最高的市場份額。
Cloud-based deployment is expected to hold the largest share in the pharmaceutical MES market due to its scalability, faster implementation, and lower infrastructure costs. Pharmaceutical manufacturers increasingly prefer cloud MES for multi-site standardization, centralized data management, and seamless integration with LIMS, ERP, and digital quality systems. It also supports real-time analytics, remote monitoring, and rapid updates while maintaining strong data integrity and compliance with 21 CFR Part 11 and global GMP standards. The growing adoption of digital, paperless manufacturing further boosts demand for cloud-based MES.
由於其可擴展性、更快的實施時間和較低的基礎設施成本，預計基於雲的部署將佔據製藥MES市場的最大份額。製藥製造商越來越傾向於使用雲MES進行多站點標準化、集中數據管理以及與LIMS、ERP和數字質量系統的無縫集成。它還支持實時分析、遠程監控和快速更新，同時保持強大的數據完整性和符合21 CFR Part 11及全球GMP標準。對數字化、無紙化製造的日益採用進一步提升了對基於雲的MES的需求。
The services offering is projected to dominate the pharmaceutical MES market in 2025.
預計到2025年，服務類將在製藥MES市場中佔據主導地位。
In the pharmaceutical MES market, service offerings hold the largest share because pharmaceutical manufacturers rely heavily on expert support to ensure compliant and efficient MES deployment. Services such as consulting, system integration, validation, implementation, training, and ongoing maintenance are essential for meeting strict GMP and FDA regulatory requirements. As pharmaceutical plants modernize their operations, they require tailored integration with ERP, LIMS, and automation systems, driving a high demand for specialized service providers. Additionally, continuous upgrades, support, and performance optimization further strengthen the dominance of the services segment in this market.
在製藥MES市場中，服務類佔據了最大的份額，因爲製藥製造商嚴重依賴專家支持來確保合規且高效的MES部署。諮詢、系統集成、驗證、實施、培訓和持續維護等服務對於滿足嚴格的GMP和FDA法規要求至關重要。隨着製藥廠現代化其運營，他們需要與ERP、LIMS和自動化系統的定製集成，這推動了對專業服務提供商的高需求。此外，持續升級、支持和性能優化進一步增強了服務類在此市場中的主導地位。
Inquiry Before Buying:
購買前諮詢：
The North America region for the pharmaceutical MES market is expected to hold the largest share in 2030.
預計到2030年，北美地區的製藥MES市場將佔據最大的份額。
North America contributes the largest share of the pharmaceutical MES industry due to its highly advanced and regulated pharmaceutical manufacturing ecosystem, strong presence of leading MES vendors, and strict FDA guidelines that mandate data integrity, electronic batch records, and GMP compliance. The region's rapid adoption of Industry 4.0, automation, and digital quality systems further accelerates MES integration. Additionally, high R&D investment, growth in biologics and personalized therapies, and the need for efficient, compliant production drive strong MES uptake across the US and Canadian facilities.
北美佔據了製藥MES行業最大的份額，這是由於其高度先進且受監管的製藥製造生態系統、領先的MES供應商的強大存在以及嚴格要求數據完整性、電子批記錄和GMP合規的FDA指南。該地區快速採用工業4.0、自動化和數字質量系統進一步加速了MES的集成。此外，高額研發投入、生物製品和個性化療法的增長以及對高效、合規生產的迫切需求推動了美國和加拿大工廠對MES的強烈需求。
Key Players
主要參與者
Leading players in the pharmaceutical MES companies include Siemens (Germany, Dassault Systèmes (France), SAP SE (Germany), ABB (Switzerland), Rockwell Automation (US), Honeywell International Inc. (US), Emerson Electric Co. (US), Yokogawa Electric (Japan), Schneider Electric (France), and others.
領先的製藥MES公司包括西門子（德國）、達索系統（法國）、SAP SE（德國）、ABB（瑞士）、羅克韋爾自動化（美國）、霍尼韋爾國際公司（美國）、艾默生電氣公司（美國）、橫河電機（日本）、施耐德電氣（法國）等。
Get 10% Free Customization on this Report:
獲取此報告的10%免費定製：
Browse Adjacent Market: Semiconductor and Electronics Market Research Reports &Consulting
瀏覽相鄰市場：半導體與電子市場研究報告及諮詢
See More Latest Semiconductor Reports:
查看更多最新半導體報告：
Gas Sensor Market By Gas Type (Oxygen, Carbon Monoxide, Carbon Dioxide, Volatile Organic Compounds, Hydrocarbons), Technology (Electrochemical, Infrared, Solid-State/Metal-Oxide-Semiconductors), Output Type, Connectivity- Global Forecast to 2033
氣體傳感器市場按氣體類型（氧氣、一氧化碳、二氧化碳、揮發性有機化合物、碳氫化合物）、技術（電化學、紅外、固態/金屬氧化物半導體）、輸出類型、連接性——全球預測至2033年
Hybrid Bonding Market By Wafer-to-Wafer (W2W), Die-to-Wafer (D2W), Die-to-Die (D2D), Wafer Bonder, Surface Prep Tool, Inspection & Metrology Tool, Cleaning & CMP System, 2.5D Packaging, and 3D Stacked IC - Global Forecast to 2032
混合鍵合市場按晶圓到晶圓 (W2W)、芯片到晶圓 (D2W)、芯片到芯片 (D2D)、晶圓鍵合機、表面準備工具、檢測與計量工具、清洗與CMP系統、2.5D封裝和3D堆疊IC - 全球預測至2032年
About MarketsandMarkets
關於MarketsandMarkets
MarketsandMarkets has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
根據《福布斯》最近的報告，MarketsandMarkets被評爲美國最佳管理諮詢公司之一。
MarketsandMarkets is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
MarketsandMarkets是增長諮詢和項目管理領域的藍海替代方案，利用人機結合的服務推動B2B領域進步組織的超常增長。憑藉對新興技術最廣泛的視野，我們擅長與全球客戶共同創造超常增長。
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
如今，80%的《財富》2000強公司依賴MarketsandMarkets，每個行業的前100家公司中有90家信任我們加速其收入增長。憑藉遍佈全球的超過13,000家客戶，我們幫助企業在一個顛覆性的生態系統中蓬勃發展。
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
B2B經濟正在見證本十年內出現的25萬億美元的新收入流，這些新收入流正在取代現有的收入來源。我們通過增長計劃與客戶合作，幫助他們通過我們的服務線實現這一25萬億美元的機會——包括總可尋址市場（TAM）擴展、進入市場（GTM）戰略到執行、市場份額提升、帳戶賦能和思想領導力營銷。
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore, which integrates research and provides ecosystem-wide visibility into revenue shifts.
基於『GIVE Growth』原則，我們與多家福布斯全球2000強B2B公司合作，幫助它們保持未來競爭力。我們的洞察和策略由行業專家、尖端人工智能以及我們的市場情報雲平台KnowledgeStore提供支持，該平台整合研究並提供生態系統範圍內的收入變化可見性。
To find out more, visit .com or follow us on Twitter, LinkedIn and Facebook.
欲了解更多信息，請訪問 .com 或在 Twitter、LinkedIn 和 Facebook 上關注我們。
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Web Site:
Research Insight:
Content Source:
聯繫：
羅翰·薩爾加卡爾先生
市場與市場公司
國會大道南1615號
103套房，德爾雷海灘，佛羅里達州，郵編33445
美國：+1-888-600-6441
郵箱: [email protected]
訪問我們的網站：
研究洞察：
內容來源：
Logo:
Logo:
SOURCE MarketsandMarkets
來源：MarketsandMarkets
21%
21%
譯文內容由第三人軟體翻譯。
